ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Hoffmann-La Roche and Hanmi Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Hoffmann-La RocheHanmi Pharmaceutical
studies on the registry2,744191
open to participants now11512
phase 3 studies under way953
reach primary completion within a year778
programswith a study of their own in two years80+25 named only12

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseHoffmann-La RocheHanmi Pharmaceutical
Phase 1

Hoffmann-La Roche: 33 of its 80 programs at phase 1

  1. RAY121phase 1
  2. clesitamigphase 1
  3. P-CD19CD20-ALLO1 Cellsphase 1
  4. Anti-c-Met Antibody-drug Conjugate YL211phase 1
  5. Anti-CDH17 Antibody-drug Conjugate HS-20110phase 1

and 28 more — sign in to see them all

41%

Hanmi Pharmaceutical: 4 of its 12 programs at phase 1

  1. HIP2503phase 1
  2. HM17321phase 1
  3. IL-2 Mutein/Fc Fusion Protein HM16390phase 1
  4. RLD2606phase 1
33%
Phase 2

Hoffmann-La Roche: 18 of its 80 programs at phase 2

  1. tifeglipronphase 2
  2. autogene cevumeranphase 2
  3. hyaluronidase (human recombinant)phase 2
  4. RO7568282phase 2
  5. tambotatug pelitecanphase 2

and 13 more — sign in to see them all

23%

Hanmi Pharmaceutical: 3 of its 12 programs at phase 2

  1. belvarafenibphase 2
  2. HM15275phase 2
  3. cobimetinibphase 2
25%
Phase 3

Hoffmann-La Roche: 22 of its 80 programs at phase 3

  1. inavolisibphase 3
  2. afimkibartphase 3
  3. giredestrantphase 3
  4. divarasibphase 3
  5. glofitamabphase 3

and 17 more — sign in to see them all

28%

Hanmi Pharmaceutical: 5 of its 12 programs at phase 3

  1. efpeglenatidephase 3
  2. HCP1306phase 3
  3. HCP1803-4phase 3
  4. hip2602phase 3
  5. hpp2602-2phase 3
42%
Approved, new studies

Hoffmann-La Roche: 7 of its 80 programs at approved, new studies

  1. ocrelizumabapproved, new study
  2. Ranibizumabapproved, new study
  3. emicizumabapproved, new study
  4. faricimabapproved, new study
  5. Trastuzumabapproved, new study

and 2 more — sign in to see them all

9%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Hoffmann-La Roche28 readouts · 7 phase 3

Hoffmann-La Roche, Nov ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. cevostamabphase 3 · Nov 18 · NCT05646836
  2. emicizumabapproved, new study · Nov 19 · NCT05181618
  3. nivegacetorphase 2 · Nov 19 · NCT06402838
  4. divarasibphase 3 · Nov 30 · NCT04302025

Hoffmann-La Roche, Dec ’26: 4 programs whose next study reaches primary completion

  1. RG6496phase 1 · Dec 1 · NCT07246941
  2. tifeglipronphase 2 · Dec 7 · NCT06982131
  3. afimkibartphase 3 · Dec 31 · NCT05910528
  4. inavolisibphase 3 · Dec 31 · NCT03006172

Hoffmann-La Roche, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. faricimabapproved, new study · Jan 26 · NCT05224102

Hoffmann-La Roche, Feb ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Ranibizumabapproved, new study · Feb 4 · NCT04657289

Hoffmann-La Roche, Mar ’27: 4 programs whose next study reaches primary completion

  1. pegozaferminphase 3 · Mar 2 · NCT07835243
  2. glofitamabphase 3 · Mar 22 · NCT06624085
  3. RAY121phase 1 · Mar 31 · NCT06371417
  4. RO7812653phase 1 · Mar 31 · NCT07234942

Hoffmann-La Roche, Apr ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. enicepatidephase 3 · Apr 8 · NCT07626515
  2. Crovalimabphase 3 · Apr 18 · NCT04432584
  3. baloxavirphase 3 · Apr 30 · NCT07827599

Hoffmann-La Roche, May ’27: 1 program whose next study reaches primary completion

  1. RO7806881phase 1 · May 11 · NCT07271693

Hoffmann-La Roche, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. fenebrutinibphase 3 · Jun 8 · NCT07161258
  2. DONQ52phase 2 · Jun 15 · NCT07239336
  3. RO7890597phase 1 · Jun 15 · NCT07797478
  4. astegolimabphase 3 · Jun 30 · NCT05878769

Hoffmann-La Roche, Jul ’27: 2 programs whose next study reaches primary completion

  1. giredestrantphase 3 · Jul 31 · NCT03332797
  2. trontinemabphase 3 · Jul 31 · NCT04639050

Hoffmann-La Roche, Aug ’27: 2 programs whose next study reaches primary completion

  1. RO7837195phase 2 · Aug 25 · NCT06979336
  2. bizrolertinibphase 3 · Aug 31 · NCT05593094

Hoffmann-La Roche, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zemocimigphase 3 · Sep 23 · NCT07416526

Hoffmann-La Roche, Oct ’27: 1 program whose next study reaches primary completion

  1. mosunetuzumabphase 3 · Oct 1 · NCT05207670
Hanmi Pharmaceutical6 readouts · 3 phase 3··

Hanmi Pharmaceutical, Jan ’27: 1 program whose next study reaches primary completion

  1. HM15275phase 2 · Jan 0 · NCT07205900

Hanmi Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion

  1. RLD2606phase 1 · Feb 5 · NCT07939087

Hanmi Pharmaceutical, Mar ’27: 1 program whose next study reaches primary completion

  1. HM17321phase 1 · Mar 0 · NCT07219589
·····

Hanmi Pharmaceutical, Sep ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. hip2602phase 3 · Sep 0 · NCT07899073
  2. hpp2602-2phase 3 · Sep 0 · NCT07899073

Hanmi Pharmaceutical, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. HCP1803-4phase 3 · Oct 30 · NCT07660796
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Hoffmann-La Roche

New programs 4

  • RO7836748phase 1 · first study · Oct 23
  • RO7821657phase 1 · first study · Oct 14
  • RO7965032phase 2 · first study · Sep 25 · Geographic Atrophy
  • RO7830698phase 2 · first study · Sep 11 · Pulmonary Disease, Chronic Obstructive

Reached a new phase 1

Study stopped 1

  • RO7763505phase 1 · terminated Nov 17 · none of its studies left running“The development of RO7763505 for coronary artery disease has been discontinued.” · NCT07495813

Primary completion later 11

Hanmi Pharmaceutical

New programs 3

  • RLD2606phase 1 · first study · Nov 10
  • hip2602phase 3 · first study · Oct 20 · Erectile Dysfunction
  • hpp2602-2phase 3 · first study · Oct 20 · Erectile Dysfunction

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 10 in all. A program counts in each condition its studies name most.

ConditionHoffmann-La RocheHanmi Pharmaceutical
Obesityboth · compare here

Hoffmann-La Roche in Obesity: 5 programs

  1. enicepatidephase 3
  2. petrelintidephase 3
  3. emugrobartphase 3
  4. tifeglipronphase 2
  5. HM17321no phase

Their studies: Hoffmann-La Roche’s studies of Obesity in search

Hanmi Pharmaceutical in Obesity: 3 programs

  1. efpeglenatidephase 3
  2. HM15275phase 2
  3. HM17321phase 1

Their studies: Hanmi Pharmaceutical’s studies of Obesity in search

Colorectal Neoplasmsboth · compare here

Hoffmann-La Roche in Colorectal Neoplasms: 5 programs

  1. inavolisibphase 3
  2. divarasibphase 3
  3. autogene cevumeranphase 2
  4. Lead Pb 203-DOTAMphase 1
  5. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Colorectal Neoplasms in search

Hanmi Pharmaceutical in Colorectal Neoplasms: 1 program

  1. cobimetinibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Colorectal Neoplasms in search

Neoplasmsboth · compare here

Hoffmann-La Roche in Neoplasms: 4 programs

  1. inavolisibphase 3
  2. lorlatinibphase 1
  3. Pan-RAS Inhibitor RG6505phase 1
  4. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Neoplasms in search

Hanmi Pharmaceutical in Neoplasms: 2 programs

  1. belvarafenibphase 2
  2. cobimetinibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Neoplasms in search

Carcinoma, Non-Small-Cell Lungboth · compare here

Hoffmann-La Roche in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. divarasibphase 3
  2. tambotatug pelitecanphase 2
  3. AQUA07phase 1
  4. lorlatinibphase 1

Their studies: Hoffmann-La Roche’s studies of Carcinoma, Non-Small-Cell Lung in search

Hanmi Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 1 program

  1. cobimetinibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Diabetes Mellitus, Type 2both · compare here

Hoffmann-La Roche in Diabetes Mellitus, Type 2: 3 programs

  1. enicepatidephase 3
  2. emugrobartphase 3
  3. tifeglipronphase 2

Their studies: Hoffmann-La Roche’s studies of Diabetes Mellitus, Type 2 in search

Hanmi Pharmaceutical in Diabetes Mellitus, Type 2: 2 programs

  1. efpeglenatidephase 3
  2. HM15275phase 2

Their studies: Hanmi Pharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

Melanomaboth · compare here

Hoffmann-La Roche in Melanoma: 1 program

  1. autogene cevumeranphase 2

Their studies: Hoffmann-La Roche’s studies of Melanoma in search

Hanmi Pharmaceutical in Melanoma: 2 programs

  1. belvarafenibphase 2
  2. cobimetinibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Melanoma in search

Neoplasm Metastasisboth · compare here

Hoffmann-La Roche in Neoplasm Metastasis: 2 programs

  1. inavolisibphase 3
  2. giredestrantphase 3

Their studies: Hoffmann-La Roche’s studies of Neoplasm Metastasis in search

Hanmi Pharmaceutical in Neoplasm Metastasis: 1 program

  1. belvarafenibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Neoplasm Metastasis in search

Diabetes Mellitusboth · compare here

Hoffmann-La Roche in Diabetes Mellitus: 1 program

  1. enicepatidephase 3

Their studies: Hoffmann-La Roche’s studies of Diabetes Mellitus in search

Hanmi Pharmaceutical in Diabetes Mellitus: 1 program

  1. efpeglenatidephase 3

Their studies: Hanmi Pharmaceutical’s studies of Diabetes Mellitus in search

Hypertensionboth · compare here

Hoffmann-La Roche in Hypertension: 1 program

  1. zilebesiranphase 3

Their studies: Hoffmann-La Roche’s studies of Hypertension in search

Hanmi Pharmaceutical in Hypertension: 1 program

  1. HCP1803-4phase 3

Their studies: Hanmi Pharmaceutical’s studies of Hypertension in search

Ovarian Neoplasmsboth · compare here

Hoffmann-La Roche in Ovarian Neoplasms: 1 program

  1. giredestrantphase 3

Their studies: Hoffmann-La Roche’s studies of Ovarian Neoplasms in search

Hanmi Pharmaceutical in Ovarian Neoplasms: 1 program

  1. cobimetinibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Ovarian Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetHoffmann-La RocheHanmi Pharmaceutical
GLP1Renicepatideefpeglenatiderule
UCN2HM17321ruleHM17321rule
A target, or a pathogen for a vaccine, known for: Hoffmann-La Roche 40 of 80 · Hanmi Pharmaceutical 5 of 12 programs (24 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Hoffmann-La Roche: 25).